Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P30305

UPID:
MPIP2_HUMAN

ALTERNATIVE NAMES:
Dual specificity phosphatase Cdc25B

ALTERNATIVE UPACC:
P30305; D3DVY1; D3DVY2; D3DVY3; D3DVY4; O43551; Q13971; Q5JX77; Q6RSS1; Q9BRA6

BACKGROUND:
The protein known as M-phase inducer phosphatase 2, or Dual specificity phosphatase Cdc25B, is essential for cell division. It ensures the transition from G2 to M phase and facilitates cytokinesis, directly targeting CDK1 to promote its activity. This regulatory action is dosage-dependent, highlighting its importance in maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of M-phase inducer phosphatase 2 offers a pathway to novel therapeutic interventions. Given its integral role in cell cycle control, targeting this phosphatase could yield breakthroughs in treating proliferative disorders, including various cancers.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.